Form 4: Quince Therapeutics Director, David Lamond, Acquires 27,000 Employee Stock Options
SEC Form 4 Filing
Director David Lamond acquired 27,000 employee stock options in Quince Therapeutics, Inc. on June 5, 2024.
Summary
- On June 5, 2024, David Lamond, a director of Quince Therapeutics, Inc., acquired 27,000 employee stock options.
- The exercise price of these options is $0.82.
- The options vest 100% on the one-year anniversary of the grant date, June 5, 2025.
- The options expire on June 5, 2034.
- Following the transaction, Lamond directly owns 27,000 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock option grants. It doesn't inherently indicate positive or negative performance, but rather provides transparency.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- Shareholders may view this as a sign of confidence from a director in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: David Lamond acquired 27,000 employee stock options. |
| 06/05/2025 | Vesting date: 100% of the shares subject to the stock option will vest. |
| 06/05/2034 | Expiration date of the stock options. |
| 06/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.